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20 The Journal of Thoracic and Cardion this issue of the Journal, Clark and coworkers1 conclude that pretreatment
with statins before cardiac surgery decreases perioperative morbidity and mor-
tality. The beneficial effects of statins were seen primarily in patients undergo-
ng coronary artery bypass grafting (CABG). Although perioperative mortality was
ower in valve patients receiving statins, this did not reach statistical significance,
ost likely because of reduced sample size.
There were several important limitations in the design of this study. It was
etrospective and nonrandomized, and variable doses and types of statins were used.
e are not told what the length of treatment was before surgical intervention.
urthermore, the dosages of statins were not targeted to achieve a specific low-
ensity lipoprotein (LDL) level, as suggested by the most recent Adult Treatment
anel guidelines.2 In fact, LDL levels were not reported for either group, and
herefore it is not known whether the beneficial effects of statins were due to
holesterol lowering or to their pleiotropic properties. Although propensity score
nalyses were used to match the patients, it is obvious that the patients who received
tatins also received a higher incidence of -blockers, angiotensin-converting en-
yme inhibitors, and aspirin therapy. In short, they had more complete cardiopro-
ection, and although statistical analyses were undertaken to account for these
iscrepancies, the perception is that statin-treated patients were better prepared for
urgical intervention and were more aggressively treated for risk factors by their
nternists and cardiologists. Studies have clearly demonstrated that patients receiving
he combination of statins, angiotensin-converting enzyme inhibitors, -blockers, and
spirin have significantly better survival after an acute coronary event.
Can we therefore conclude from this study that all patients undergoing
ardiac surgery should receive statin therapy preoperatively? Should prospective
andomized studies be performed to define the optimal dose, length of therapy,
nd specific statin for the cardiac surgical patient? Are further studies necessary
o elucidate the mechanism for the beneficial effects of statins in the perioper-
tive period? In short, are more data necessary?
avorable Effects of Statins in Patients With Coronary Disease
umerous clinical trials have shown that statin therapy improves survival and
educes ischemic events in patients with known coronary disease. These bene-
cial effects were seen irregardless of age, baseline LDL level, and the presence
r absence of cardiac risk factors. In view of this, recent Adult Treatment Panel
uidelines now recommend lowering LDL levels to less than 100 mg/dL in
atients with known coronary disease and more aggressive statin therapy to
ower LDL levels to less than 70 mg/dL for patients with coronary disease with
he highest risk factors, which include diabetes, hypertension, obesity, smoking,
he metabolic syndrome, and acute coronary syndromes (ACSs).2 The dose
f the statin should be sufficient to achieve at least a 30% to 40% reduction in
DL levels. On the basis of these guidelines, all patients undergoing CABG
hould receive statin therapy before surgical intervention irregardless of their
aseline LDL level. Experimental studies in a porcine CABG model have
ocumented that the favorable effects of pretreatment with statins occur even in
he face of relatively normal LDL values.
vascular Surgery ● March 2006
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Ltatin Therapy in Patients Requiring Urgent
nd Emergency CABG
an statin therapy be equally effective in patients presenting
ith ACSs requiring urgent or emergency CABG in whom
tatin therapy can only be initiated less than 24 hours before
urgical intervention? In a meta-analysis of 300,823 patients
ospitalized for an acute myocardial infarction, the initia-
ion of statin therapy within 24 hours of the infarction was
ssociated with significantly lower rates of morbidity and
ortality.3 Mortality was reduced from 15.4% to 4.0%, and
here was a lower incidence of cardiogenic shock, arrhyth-
ias, cardiac arrest, and rupture. A recent review of 6
andomized controlled intervention trials involving patients
ith ACSs concluded that early initiation of high-intensity
tatin therapy (80 mg/d atorvastatin) reduced recurrent isch-
mic events compared with moderate-intensity treatment
40 mg of pravastatin).4 Moderate-intensity regimens (40
g of simvastatin, 20-40 mg of pravastatin, 80 mg of
uvastatin, and 0.4 mg of cerivastatin) provided minimal
enefit compared with placebo. The anti-inflammatory prop-
rties of intensive statin therapy might be responsible for
hese beneficial effects because high-dose (80 mg) atorva-
tatin resulted in a 35% reduction of C-reactive protein
CRP) levels, with far less effects on LDL levels. These
tudies strongly suggest that all patients experiencing ACSs
ill benefit from intensive statin therapy, even if the drug is
egun less than 24 hours from the time of infarction. Hence
atients requiring urgent or emergency CABG will also
enefit from the cardioprotection provided by statin therapy,
ven if initiated immediately before surgical intervention,
rovided that more intensive doses are used.
echanisms for the Beneficial Effects
f Statins in the Patient Undergoing CABG
f statins exert their beneficial effects in the acutely isch-
mic patient without dramatic changes in LDL levels, what
s the mechanism responsible for the cardioprotective ef-
ects of statins in patients with ACSs? Statins have been
hown to work through intermediate pathways to improve
ndothelial function, reduce the inflammatory process, and
ecrease thrombosis independent of their LDL-lowering
roperties. Statins enhance endothelial function by decreas-
ng superoxide formation, upregulating the expression of
ndothelial nitric oxide synthase, and inhibiting the release
f angiotensin II and endothelin. They reduce inflammation
y decreasing levels of CRP and reducing cytokine and
dhesion molecule expression. Thrombosis is suppressed
nd fibrinolysis is enhanced by reducing platelet aggrega-
ion and adhesion and thromboxane formation and promot-
ng fibrinolysis by enhancing tissue plasminogen activator
ynthesis and reducing tissue plasminogen activator inhib-
tor levels. These pleiotropic effects appear to be indepen-
ent of LDL lowering and can occur within 24 hours of
nitiation of therapy but require higher doses of statins. a
The Journal of Thoracicosages, Types of Statins, and Safety Issues
ost patients undergoing CABG surgery will require higher
oses of statin therapy. However, are higher doses of statin
herapy safe, and are all statins equal in their cardioprotec-
ive effects? Eighty milligrams of atorvastatin is the most
ommon high-intensity statin used and has been associated
ith better outcomes in patients compared with moderate
oses with other statins. Hence it is important to compare
he safety of this dosage regimen with that of other statin
gents.
The most serious side effect associated with statins
s rhabdomyolysis. The highest risk for this complication
as associated with cerivastatin (3.16 per million prescrip-
ions), which is no longer on the market. The risk for other
tatins per million prescriptions is as follows: 0.19 for
ovastatin, 0.12 for simvastatin and pravastatin, 0.04 for
torvastatin, and 0 for fluvastatin. The risk for rhabdomy-
lysis is associated with factors that increase serum concen-
rations of statins, such as small body size, advanced age,
enal or hepatic dysfunction, diabetes, hypothyroidism, and
rugs that interfere with statin metabolism, such as cyclo-
porin, antifungal agents, calcium-channel blockers, and
miodarone. High-dose atorvastatin has been associated
ith few side effects. In 44 atorvastatin trials, adverse
vents, such as liver dysfunction and myopathy, occurred
ith equal frequency in the placebo group and at each
torvastatin dose. In contrast, 80 mg of simvastatin is asso-
iated with a low but definitive increased risk of myopathy
0.4%). Hence the benefits of high-dose statin therapy ap-
ear to outweigh any potential risks.
tatins and Valve Surgery
lthough the data are clear that statins benefit all patients
ndergoing CABG, the data are less convincing for patients
ndergoing isolated valve surgery. There is evidence to
uggest that the inflammatory response seen in atheroscle-
otic vascular disease might also be responsible for the
rogression of calcific deposits seen on native and biopros-
hetic valves. Patients with high serum cholesterol levels
ave more rapid progression of aortic valve calcification
nd decreased aortic valve orifice areas. Aortic valve calci-
cation has also been associated with higher levels of CRP
nd endothelial dysfunction. In the past, the cause of valve
alcification has been thought to be degenerative processes,
ut there is now evidence to suggest that LDL receptor
roteins might play an important role in osteoblast differ-
ntiation and skeletal bone formation. Atorvastatin signifi-
antly reduced aortic valve calcification in cholesterol-fed
nimals by reducing LDL receptor–related proteins respon-
ible for osteoblast formation. Several clinical studies have
uggested that statins might restrict the progression of aortic
clerosis, as assessed by means of echocardiography-derived
ortic valve areas and mean gradients in dosages that had little
and Cardiovascular Surgery ● Volume 131, Number 3 521
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Lffect on LDL lowering. Primary tissue failure of bioprosthetic
alves is also related to calcification and inflammation similar
o that seen in native valve disease. Farivar and Cohn5 found
hat patients with explanted bioprosthetic valves had higher
holesterol levels and a lower incidence of statin use. Antonini-
anterin and colleagues6 noted a decrease in annual mean
radients and the rate of decrease in effective orifice area in
ortic bioprostheses in the presence of statin therapy. However,
oth of these studies were retrospective and nonrandomized,
nd the types of statins used, their dosages, and duration of
herapy were not controlled. Specific levels of LDL were not
argeted. Bioprosthetic valves show their greatest incidence of
eterioration after 7 years; however, none of these studies
xceeded a mean follow-up of 4 years. Therefore the true
ffect of statin therapy on the durability of bioprosthetic valves
s unknown.
onclusions
hould all patients receive statins before cardiac surgery,
nd are more data necessary? Data from numerous random-
zed clinical trials strongly suggest that all patients under-
oing CABG should receive statins before surgical inter-
ention. Patients undergoing elective operations should
eceive dosages of statins targeted to achieve LDL levels
f less than 100 mg/dL and even lower (70 mg/dL) for
igh-risk cases. Patients requiring urgent or emergency
ABG should have high-dose statin therapy initiated as
oon as the decision is made to proceed with the operation.
torvastatin at 80 mg would appear to be the statin of
hoice for these patients on the basis of its superior results
n trials involving patients with ACSs. Statin therapy should
e initiated in these patients, irregardless of their baseline
DL levels. On the basis of previous CABG trials showing
ignificantly improved graft patency, decreased need for repeat
evascularization, and lower incidence of ischemic cardiovas-
ular events, all patients undergoing CABG should receive
ifetime statin therapy. The benefits far outweigh the minimal
isks of toxicity with these drugs.
22 The Journal of Thoracic and Cardiovascular Surgery ● MarcThe role of statin therapy remains less clear in patients
ndergoing isolated valve surgery. I suspect that statins will
ave a cardioprotective effect in patients undergoing iso-
ated aortic and mitral valve replacement for calcific
tenosis and will enhance the longevity of bioprostheses
mplanted in these patients. However, only prospective,
ulticenter, randomized trials with specified dosages of
tatins to achieve a target LDL level can provide the defin-
tive answer for the role of statin therapy in these patients.
hese studies take time, are expensive, and might not be
unded by pharmaceutical companies when patents are near
xpiration. In the meantime, I have begun to initiate statin
herapy in patients with aortic and mitral stenosis and in all
atients receiving a bioprosthetic valve, irregardless of their
aseline LDL level. Although more data are necessary, the
ncreased benefits of early cardioprotection and potential for
nhanced bioprosthetic durability appear to outweigh the
inimal risks involved with these drugs.
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